Please login to the form below

Not currently logged in

Sagent appoints Michael Fekete to board

Will support growth of injectables firm following initial public offering

Sagent Pharmaceuticals has appointed Michael Fekete as the sixth member of its board of directors.

Fekete is currently director at both pharma firm DFB Pharmaceuticals and Symetis SA, which creates minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases.

He is a corporate adviser specialising in capital markets, mergers and acquisitions and general corporate strategy and has experience at Oppenheimer & Co and L F Rothschild & Co.

Illinois, US-based injectable specialist Sagent will benefit from his advice as it looks to expand following its successful initial public offering, which Fekete assisted in an advisory role.

“Mike's experience and skill set will be particularly valuable to us as we continue to drive our growth,” said Jeffrey Yordon, founder, CEO and chairman of the board of Sagent.

“We look forward to his contribution to the board of directors and his involvement with senior management of the company."

16th July 2013


Featured jobs

Subscribe to our email news alerts


Add my company

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...